HCW Biologics is trading at $3.70 (up 10.8%) as investors react to continued momentum following a recent insider share purchase by CEO Hing Wong.
- The rally extends from a July 29 disclosure where Wong purchased shares at $2.59, a move interpreted by the market as a significant signal of internal confidence.
- Shares are climbing from an August 03, 2026, close of $3.34, further supported by a broader risk-on sentiment currently observed in U.S. futures.